| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/18/2023 | — | Raymond James | Downgrades | Outperform → Market Perform | |
| 08/03/2023 | 16.87% | JMP Securities | $11 → $11.5 | Maintains | Outperform |
| 05/03/2023 | 6.71% | Raymond James | $13.5 → $10.5 | Maintains | Outperform |
| 05/03/2023 | 11.79% | JMP Securities | $13.5 → $11 | Maintains | Outperform |
| 04/24/2023 | -8.54% | JP Morgan | $11 → $9 | Maintains | Neutral |
| 04/13/2023 | 1.63% | Keefe, Bruyette & Woods | $12.5 → $10 | Maintains | Market Perform |
| 03/08/2023 | 27.03% | Keefe, Bruyette & Woods | → $12.5 | Downgrades | Outperform → Market Perform |
| 10/31/2022 | 32.11% | B of A Securities | → $13 | Reinstates | → Buy |
| 10/24/2022 | 21.95% | JP Morgan | $13.5 → $12 | Maintains | Neutral |
| 10/18/2022 | 37.2% | Raymond James | $15 → $13.5 | Maintains | Outperform |
| 10/14/2022 | 37.2% | JMP Securities | $15 → $13.5 | Maintains | Market Outperform |
| 08/01/2022 | 52.44% | JMP Securities | $16.5 → $15 | Maintains | Market Outperform |
| 07/18/2022 | 52.44% | Raymond James | $16.5 → $15 | Maintains | Outperform |
| 04/25/2022 | 62.6% | JP Morgan | $14.5 → $16 | Maintains | Neutral |
| 03/31/2022 | 67.68% | JMP Securities | $16 → $16.5 | Maintains | Market Outperform |
| 11/04/2021 | 72.76% | JMP Securities | $16.5 → $17 | Maintains | Market Outperform |
| 05/05/2021 | 67.68% | Raymond James | $15 → $16.5 | Maintains | Outperform |
| 03/17/2021 | 62.6% | Credit Suisse | $13 → $16 | Maintains | Outperform |
| 02/19/2021 | 52.44% | Raymond James | $12 → $15 | Maintains | Outperform |
| 11/20/2020 | 21.95% | Raymond James | $11 → $12 | Downgrades | Strong Buy → Outperform |
| 06/30/2020 | 6.71% | Keefe, Bruyette & Woods | → $10.5 | Upgrades | Market Perform → Outperform |
| 04/22/2020 | 1.63% | JMP Securities | $16 → $10 | Maintains | Market Outperform |
| 04/13/2020 | 11.79% | Raymond James | $16 → $11 | Maintains | Strong Buy |
| 02/25/2020 | 67.68% | JP Morgan | $16 → $16.5 | Maintains | Neutral |
| 02/21/2020 | 77.85% | Credit Suisse | $16 → $17.5 | Maintains | Outperform |
| 01/08/2020 | 62.6% | Credit Suisse | $15.5 → $16 | Upgrades | Neutral → Outperform |
| 01/11/2019 | — | Raymond James | Upgrades | Outperform → Strong Buy | |
| 10/24/2018 | 47.36% | JP Morgan | $14 → $14.5 | Maintains | Neutral |
| 10/09/2018 | 52.44% | BTIG | → $15 | Initiates Coverage On | → Buy |
| 08/21/2018 | 47.36% | Credit Suisse | $14 → $14.5 | Maintains | Neutral |
What is the target price for Ares Comml Real Est (ACRE)?
The latest price target for Ares Comml Real Est (NYSE: ACRE) was reported by Raymond James on August 18, 2023. The analyst firm set a price target for $0.00 expecting ACRE to fall to within 12 months (a possible -100.00% downside). 11 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Ares Comml Real Est (ACRE)?
The latest analyst rating for Ares Comml Real Est (NYSE: ACRE) was provided by Raymond James, and Ares Comml Real Est downgraded their market perform rating.
When is the next analyst rating going to be posted or updated for Ares Comml Real Est (ACRE)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Ares Comml Real Est, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Ares Comml Real Est was filed on August 18, 2023 so you should expect the next rating to be made available sometime around August 18, 2024.
Is the Analyst Rating Ares Comml Real Est (ACRE) correct?
While ratings are subjective and will change, the latest Ares Comml Real Est (ACRE) rating was a downgraded with a price target of $0.00 to $0.00. The current price Ares Comml Real Est (ACRE) is trading at is $9.84, which is out of the analyst's predicted range.